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This study was to explore the mechanisms underlying 1,2-dichloroethane (1,2-DCE)
induced brain edema by focusing on alteration of matrix metalloproteinase-2 (MMP-2) in
rat astrocytes induced by 2-chloroethanol (2-CE), an intermediate metabolite of 1,2-DCE
in vivo. Protein and mRNA levels of MMP-2, and the phosphorylated protein levels of
p38 MAPK (p-p38), extracellular signal regulated protein kinase (p-ERK1/2) and c-Jun
N-terminal kinase (p-JNK1/2) in astrocytes were examined by immunostaining, western
blot or real-time RT-PCR analysis. Findings from this study disclosed that protein levels
of MMP-2 were upregulated by 2-CE in astrocytes. Meanwhile, protein levels of p-p38,
p-ERK1/2 and p-JNK1/2 were also increased apparently in the cells treated with 2-CE.
Moreover, pretreatment of astrocytes with SB202190 (inhibitor of p38 MAPK), U0126
(inhibitor of ERK1/2) or SP600125 (inhibitor of JNK1/2) could suppress the upregulated
expression of p-p38, p-ERK1/2, and p-JNK1/2. In response to suppressed protein
levels of p-p38 and p-JNK1/2, the protein levels of MMP-2 also decreased significantly,
indicating that activation of MAPK signal pathways were involved in the mechanisms
underlying 2-CE-induced upregulation of MMP-2 expression.
Keywords: 1,2-dichloroethane, astrocytes, 2-chloroethanol, matrix metalloproteinase-2, mitogen-activated
protein kinase signal pathways
INTRODUCTION
The compound of 1,2-dichloroethane (1,2-DCE, CAS number: 107-06-2) is one of the most widely
produced halocarbons, and used mainly in the production of vinyl chloride worldwide. This
chemical is also used as the general organic solvent, especially as the thinner of adhesives in
some countries. It is clear that subacute poisoning of 1,2-DCE can cause toxic encephalopathy
in the exposed workers. The postmortem and clinical studies showed that brain edema is the main
pathological change and the cause of death in the poisoned workers (Liu et al., 2010; Zhang et al.,
2011; Chen et al., 2015). But so far, little is known about the molecular mechanisms underlying
1,2-DCE-induced brain edema.
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Accumulated evidences have suggested that the principal
pathway involving metabolism of 1,2-DCE is mediated by
microsomal cytochrome P450 2E1 (CYP2E1) in animals and
most probably, in humans as well (Reitz et al., 1982;
Sweeney et al., 2008). The metabolites generated in CYP2E1
mediated metabolism of 1,2-DCE are 2-chloroethanol (2-CE),
chloroacetaldehyde and chloroacetic acid. Of which, 2-CE and
chloroacetaldehyde are the reactive intermediates, and assumed
to be involved in mechanisms underlying 1,2-DCE induced brain
edema since they are more reactive than their parent compound
(Guengerich et al., 1980; Igwe et al., 1986; Raucy et al., 1993).
Hence, it is essential for exploring the neurotoxic effects induced
directly by 2-CE.
Brain edema has been classically defined as cytotoxic and
vasogenic edema referred to either intracellular or extracellular
water excess. The former is due to energy failure in injured
brain cells, while the latter results from breakdown in blood-
brain barrier (BBB) (Simard and Rivest, 2007). Recently, roles
of matrix metalloproteinases (MMPs) in the pathogenesis of
vasogenic brain edema are actively investigated. Deregulation of
MMPs, the largest class of human proteases, has been implicated
in brain damage in both animal and human studies (Morancho
et al., 2010; Iwado et al., 2012; Yan et al., 2016).
MMPs are a gene family of zinc-dependent proteases involved
in the regulation of extracellular matrix composition (Sternlicht
and Werb, 2001). As the main gelatinases in the brain, MMP-
2 and MMP-9 can degrade collagen IV and fibronectin in
microvascular basal lamina around the endothelial cells. The
tight junction proteins, occludin and claudin-5 in the endothelial
barrier, are also vulnerable to attack by MMPs. Thereby excessive
expression of MMP-2 and MMP-9 can disrupt the BBB integrity,
which might contribute to development of vasogenic brain
edema (Asahi et al., 2001a,b; Planas et al., 2001; Yang et al., 2007;
Higashida et al., 2011; Ramos-Fernandez et al., 2011; Suofu et al.,
2012). It has been reported that in most cases, the inhibitory
effects on expressions of MMP-2 and MMP-9 could reduce the
permeability of BBB at the early phase of brain edema formation
(Romanic et al., 1998; Rosenberg et al., 1998; Gasche et al., 1999).
Although MMP-2 and MMP-9 have similar substrate
specificities, the regulation ways in their expression are quite
different. A variety of studies have disclosed that MMP-2 is
constitutively expressed, and normally present in an inactive
form tethered to the cell surface; however, MMP-9 is normally
expressed at low levels but is markedly up-regulated in many
brain diseases (Senior et al., 1991; Okada et al., 1992; Nag
et al., 2009). Our recent study has demonstrated that levels of
MMP-2 protein but not its mRNA, whereas levels of MMP-
9 mRNA were increased apparently in the cerebral tissues of
mice during the brain edema formation induced by subacute
poisoning of 1,2-DCE (Wang et al., 2014). However, up to
date, little is known about the cellular source of these MMPs
or how their expression is regulated in the brain of 1,2-DCE
poisoned mice. Accordingly, the changes of MMP-2 and MMP-
9 expression, and the roles of mitogen-activated protein kinase
(MAPK) signal pathways in their regulation were explored
in 2-CE treated rat astrocytes. In this paper, the changes
of MMP-2 expression, and the involvement of MAPK signal
pathways in its regulation in 2-CE treated rat astrocytes were
reported.
Astrocytes, the most numerous cell type in the brain,
play essential roles in regulation of homeostatic balance and
maintenance of BBB integrity (Chambaut-Guérin et al., 2000;
Ransom and Ransom, 2012; Finsterwald et al., 2015). The
previous studies have disclosed that MMP-2 is expressed in
several cell types in the brain, such as astrocytes, endothelial
cells and microglia (Ogier et al., 2006; Qin et al., 2015; Maeda
et al., 2016). The in vitro studies demonstrated that MMP-2 in
rat astrocytes could be induced by the proinflammatory cytokine,
such as IL-1β and TNF-α (Gottschall and Deb, 1996; Ogier et al.,
2006; Wang et al., 2006). In addition, it has been reported that
MMP-2 was upregulated in response to transient focal cerebral
ischemia in the early stages of the injury, and then degraded the
proteins in the tight junctions of BBB, thus leading to breakdown
in BBB integrity (Chang et al., 2003; Yang et al., 2007).
The MAPK signal pathways transmit signals from cell
membrane to nucleus in response to a variety of stimuli. Because
these pathways control a broad spectrum of cellular processes,
they are accepted as the important regulators in pathogenesis
of human diseases. The most extensively studied subfamilies of
MAPK signal pathways are extracellular signal-regulated kinase
1/2 (ERK1/2), p38 MAPK (p38), and c-Jun amino terminal
kinase (JNK) (Arai et al., 2003; Tejima et al., 2007; Hsieh et al.,
2010; Ralay-Ranaivo et al., 2011). They are activated through
phosphorylation by upstream kinases recruited through diverse
extracellular signal events. Upon activation of MAPK signal
pathways, transcription factors that are present in the cytoplasm
or nucleus are activated, leading to expression of a variety of
target genes and resulting in a series of biological responses
(Hsieh et al., 2004, 2006; Wu et al., 2004).
Taken together, it was of interest to investigate the
involvement of MAPK signal pathways in modulation of MMP-
2 expression in 2-CE treated astrocytes, which would contribute
to identify new therapeutic targets for 1,2-DCE induced brain
edema. To the best of our knowledge, no studies concerning this
subject have been reported.
MATERIALS AND METHODS
Animal Care and Use Statement
All animal studies were approved by the Scientific Research
Committee of China Medical University and have been
conducted in accordance with Chinese National Guidelines for
the Care and Use of Laboratory animal in animal experiments.
Reagents
2-CE with purity more than 99.0% was obtained from the
Sinopharm Chemical Reagent Co., Ltd, China. Dulbecco’s
modified Eagle’s medium (DMEM), trypsin, penicillin and
streptomycin were purchased from Invitrogen (USA). Heat
inactivated fetal bovine serum (FBS) was the product of
Biological Industries (Israel). Trizol reagent was obtained from
Takara (Japan). RIPA Lysis Buffer was purchased from Beyotime
Biotechnology (China). The enhanced chemiluminescence (ECL)
plus kit and bicinchoninic acid (BCA) protein assay kit
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were obtained from Pierce (Thermo Fisher Scientific, USA).
The polyclonal antibody against MMP-2 was purchased from
Millipore (USA, #AB19167). The primary antibodies against
phosphorylated p38 (p-p38, #9211), phosphorylated ERK1/2
(p-ERK1/2, #4370), phosphorylated JNK1/2 (p-JNK1/2, #9251)
and β-actin (#4970) were the products of Cell Signaling
Technology (USA). SB202190, U0126, SP600125 were purchased
from Selleck (USA). Secondary antibody conjugated fluorescein
isothiocyanate (FITC), tetraethyl rhodamine isothiocyanate
(TRITC) or horseradish peroxidase were purchased from the
ZSGB Biotechnology (China). All other chemicals were of the
analytical grade and obtained from the local chemical suppliers.
These chemical reagents were prepared as stock solutions with
sterile water, and then diluted to the final concentrations before
application. Water used in this study was doubly distilled.
Primary Culture for Astrocyte
The cerebral cortices of postnatal day 1–3 Wistar rats, obtained
from the animal laboratory of China Medical University were
carefully removed, and washed three times by ice-cold Hanks
balanced salt solution without Ca2+ and Mg2+. They were
chopped into pieces less than 1 mm on each side, and then
dissociated with 0.125% (w/v) trypsin solution at 37◦C for
20 min with gentle shaking. The cell suspension was filtered
through a 200 mesh (76 µm) stainless steel screen followed
by centrifugation. Dissociated cells were suspended in DMEM
containing 20% FBS and 1% penicillin-streptomycin. They were
plated in the culture dishes pre-coated with poly-L-lysine at a
density of 1 × 106/ml, and maintained at 37◦C, in 5% CO2 and
100% humidified atmosphere with replacement of fresh medium
every 3 days.
When a confluent layer was formed, the culture dishes were
shaken for 15 h at 250 rpm in the orbital shaker to remove
oligodendrocyte precursors and microglia. Following shaking,
the medium was changed immediately, and a nearly pure layer
of astrocyte was obtained in the culture dishes. The target cells
were grown for 24 h, and then trypsinized and reseeded in
new culture dishes at a density of 1 × 105/ml. As illustrated in
Figure 1, more than 95% cells were positive for glial fibrillary
acidic protein (GFAP, a marker of astrocyte), determined by
immunofluorescence staining.
Treatments
The stock solution of 1 M (mol/L) 2-CE was prepared with
redistilled water, and then diluted to the target concentrations
by the media containing 5% FBS before application. The present
study included two parts of experiments. For part one, astrocytes
were divided randomly into four groups, the control group and
three exposure groups. The cells in these groups were exposed
to 0, 7.5, 15, or 30mM 2-CE for 24 h in the media with 5% FBS
when a confluent layer was formed. After exposure, the cells were
collected for analysis of MMP-2 expression affected by 2-CE.
For part two, the cells were divided into seven groups to
explore the involvement of MAPK signal pathways in regulation
of MMP-2 expression in astrocytes affected by 2-CE. They were
blank control, solvent control, and inhibitor control, exposure
group, and low, middle and high dose intervention groups,
FIGURE 1 | Immunofluorescence staining for GFAP. More than 95% cells
were positive for astrocyte biomarker GFAP, the photomicrographs were
captured with an Olympus fluorescence microscope (400×).
respectively. Cells in the solvent control were treated with
dimethyl sulfoxide (DMSO, the concentration in the media was
less than 0.1%). Cells in the inhibitor control were treated with
30µM SB202190, 10µM U0126, or 10 µM SP600125, which
were dissolved into DMSO, and then added into the media
(Wu et al., 2004). Cells in the exposure group and intervention
groups were exposed to 30mM 2-CE for 24 h as described above.
Moreover, cells in the intervention groups were pretreated 1 h
before exposure to 2-CE with 1, 10, and 30µM SB202190 for
inhibition of p38 (Manthey et al., 1998), 0.1, 1.0, and 10.0 µM
U0126 for inhibition of ERK1/2 (Smutny et al., 2014), or 0.1, 1.0,
and 10.0µM SP600125 for inhibition of JNK1/2 (Bennett et al.,
2001).
After treatment, these cells were collected for analysis of
protein and gene levels of MMP-2, and protein levels of p-p38,
p-ERK1/2 and p-JNK1/2.
Analysis
Immunocytochemical Staining
Briefly, cells in the 12-well culture plate were fixed with 4%
paraformaldehyde, permeabilized in 0.2% Triton X-100, and
incubated with 10% normal goat serum at room temperature
to block nonspecific binding of antiserum. They were then
incubated with primary antibodies against GFAP (1:400, mouse
anti-rat) or MMP-2 (1:100, rabbit anti-rat) at 4◦C overnight.
Labeled cells were visualized by TRITC conjugated goat anti-
mouse or FITC conjugated goat anti-rabbit secondary antibody
and observed under a fluorescence microscope (Olympus BX51).
Digital images were captured using digital camera system
(Olympus SC35). For negative controls, the primary antibodies
were omitted. All steps were carried out in a humidified chamber.
Western Blot Analysis
At the end of exposure, the cells were detached by scraping,
and harvested by centrifugation. Cell pellets were suspended
and lysed by RIPA buffer. Protein concentrations in the lysates
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were measured with a BCA protein assay kit. Aliquots of
each sample (40 µg per lane) were loaded to 10% SDS-PAGE,
and then separated by electrophoresis. Blots were transferred
onto polyvinylidene difluoride (PVDF) membranes (Millipore,
USA), and subsequently probed with the primary antibodies
against MMP-2 (1:1000, rabbit anti-rat), p-p38 (Thr180/Tyr182,
1:500, rabbit anti-rat), p-ERK1/2 (Thr202/Tyr204, 1:500, rabbit
anti-rat), p-JNK1/2 (Thr183/Tyr185, 1:500, rabbit anti-rat), and
β-actin (1:2000, rabbit anti-rat) at 4◦C overnight. The bands
were detected by the secondary antibodies conjugated with
horseradish peroxidase (1:5000) for 1 h at room temperature,
and visualized by using the ECL plus kit. The integrated
intensity of the target protein was semi-quantitatively assessed
by densitometry using an image analyzing software (Gel-Pro
analyzer v4.0), and then normalized to β-actin levels from the
same blot.
Levels of MMP-2 mRNA by Quantitative Real-Time
RT-PCR
The quantitative real-time RT-PCR was conducted according
to the Minimum Information for Publication of Quantitative
Real-Time PCR Experiments (MIQE) guidelines. Total RNA was
isolated from the cells using Trizol Reagent. At first, the cDNA
was synthesized from the total RNA by using the PrimeScript RT
reagent kit (Takara, Japan). Thereafter, the cDNA was served as
templates for real-time PCR amplification by using the SYBR R©
Premix Ex Taq
TM
II (Takara, Japan) andABI 7500 Real-Time PCR
System (Applied Biosystems, USA). Amplificationwas conducted
for 40 cycles of 5 s at 95◦C and 34 s at 60◦C. Results were
analyzed using the comparative Ct method as described by
Livak and Schmittgen (2001). RNA abundance was expressed
as 2−11Ct for the target gene normalized against the GAPDH
gene (as the reference gene), and presented as fold change versus
control sample. The following primer pairs were used: MMP-
2: sense 5′-GCA ACC ACA ACC AAC TAC GA-3′; antisense
5′-CCA GTG TCA GTA TCA GCA TCA G-3′ (NM_031054.2,
GI: 146262018). GAPDH: sense 5′-GCA AGA GAG AGG CCC
TCA G-3′; antisense 5′-TGT GAG GGA GAT GCT CAG TG-3′
(NM_017008.4, GI: 402691727).
Statistical Analysis
Data were expressed as mean ± standard deviation (SD), and
analyzed using the SPSS for Windows, version 20.0 (SPSS
Inc., USA). Significant differences among group means were
evaluated by analysis of variance test (one-way ANOVA). Post
hoc tests were analyzed by Student-Newman-Keuls (SNK) test.
The statistical significance was defined as p< 0.05.
RESULTS
Expressions of MMP-2 in Astrocytes
Affected by 2-CE Treatment
The representative micrographs in Figure 2A illustrated the
immunoreactivities to MMP-2 in the cells from different groups.
The fluorescence intensities in the exposure groups increased
apparently 15 and 30 mM 2-CE exposure groups. Consistent
with the results of immunostaining, protein levels of MMP-
2 in 30 mM 2-CE exposure groups increased significantly as
compared to the control and 7.5 mM 2-CE exposure groups (p
< 0.05, shown in Figures 2B,C). In addition, the graph shown
in Figure 2D disclosed the comparison of MMP-2 mRNA levels
among groups, and indicated that there was not any significant
difference (p< 0.05).
Accordingly, the protein expression of MMP-2 in rat
astrocytes could be upregulated confirmatively by exposure to
30 mM 2-CE. Thus, this dosage was employed in the following
studies.
Involvement of p38 in Upregulation of
MMP-2 Expression in 2-CE Treated
Astrocytes
Compared to the blank control group, the protein levels of
p-p38 and MMP-2 in the inhibitor control group decreased
significantly, whereas those in the exposure group increased
significantly (p < 0.05, shown in Figures 3A,B). Moreover, the
protein levels of p-p38 in SB202190 inhibition groups decreased
significantly as compared to the exposure group, and those
in the high dose of SB202190 inhibition group also decreased
significantly compared to other intervention groups. Consistent
with the changes of p-p38 protein levels, the MMP-2 protein
levels in the middle and high dose of SB202190 inhibition groups
decreased significantly compared to exposure group. In addition,
the graph shown in Figure 3C disclosed the comparison ofMMP-
2 mRNA levels in the cells among groups, and indicated that the
mRNA levels of MMP-2 in the inhibitor control group decreased
significantly as compared to blank control group, and those in
the middle and high dose of SB202190 inhibition groups also
decreased significantly compared to the exposure group.
Involvement of ERK in Upregulation of
MMP-2 Expression in 2-CE Treated
Astrocytes
Compared to the blank control group, the protein levels of
p-ERK1/2 in the inhibitor control group decreased significantly,
whereas those of p-ERK1/2 and MMP-2 in the exposure group
increased significantly (p < 0.05, shown in Figures 4A,B).
Moreover, the protein levels of p-ERK1/2 in the U0126 inhibition
groups decreased significantly and dose dependently; however
both protein and mRNA levels of MMP-2 in the intervention
groups did not differ significantly as compared to the exposure
group (shown in Figure 4C).
Involvement of JNK in Upregulation of
MMP-2 Expression in 2-CE Treated
Astrocytes
Compared to the blank control group, the protein levels of
p-JNK1/2 in the inhibitor control group decreased significantly,
whereas those of p-JNK1/2 and MMP-2 in the exposure group
increased significantly (p < 0.05, shown in Figures 5A,B).
Moreover, the protein levels of both p-JNK1/2 and MMP-2 in
the intervention groups decreased significantly as compared to
the exposure group, and those of p-JNK1/2 in the high dose of
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FIGURE 2 | Changes of MMP-2 protein and mRNA levels in primary cultured astrocytes exposed to 2-CE. (A) Immunofluorescence staining for MMP-2
(400×). a: control; b: 7.5mM dose; c: 15mM dose; d: 30mM dose 2-CE. (B) Western blot analysis. Images were the representative results of three separate
experiments for each group. (C) Densitometric analysis of western blots for MMP-2. The relative intensity in arbitrary units compared to β-actin and presented as fold
change vs the control group. (D) Quantitation of MMP-2 mRNA by real-time RT-PCR. The gene expression was normalized to GAPDH and presented as fold change
vs. the control group. Data expressed as mean ± SD were the results of three independent experiments from different litters of rats for each treatment, and analyzed
by One-way ANOVA. Significant difference was defined as p < 0.05, and *, vs. control; #, vs. 7.5mM dose.
SP600125 inhibition group decreased significantly as compared
to the other intervention groups. However, the protein levels
of MMP-2 did not differ significantly among the intervention
groups. On the other hand, the mRNA levels of MMP-2 did not
differ significantly between the exposure group and intervention
groups (shown in Figure 5C).
DISCUSSION
Results of present study suggested that the protein levels ofMMP-
2 in rat astrocytes could be upregulated by 2-CE treatment.
The protein levels of MMP-2 in 30mM 2-CE treated rat
astrocytes increased 523%. Similarly, our previous in vivo study
demonstrated that the protein level of MMP-2 in the brain
increased markedly at the process of 1,2-DCE induced brain
edema formation in mice (Wang et al., 2014). Collectively, these
results suggested that upregulated MMP-2 expression by both
1,2-DCE and 2-CE occurred mainly at the translational level,
including enhanced protein synthesis and decreased enzyme
degradation. Since MMP-2 is constitutively expressed, and
normally tethered to the cell surface as an inactive form after
synthesis, it might be released from the cell membrane (Ogier
Frontiers in Neuroscience | www.frontiersin.org 5 January 2017 | Volume 10 | Article 593
Sun et al. 2-Chloroethanol Upregulated MMP-2 Via MAPK
FIGURE 3 | Involvement of p38 in MMP-2 induction in primary cultured astrocytes exposed to 2-CE. I to VII represent the blank control, solvent control,
inhibitor control, exposure group, and low, middle and high dose of SB202190 inhibition group, respectively. (A)Western blot analysis. Images were the representative
results of three separate experiments for each group. (B) Densitometric analysis of western blots. The relative intensity in arbitrary units was compared to β-actin and
presented as fold change vs. the control group. (C) Quantitation of mRNA by real-time RT-PCR. The gene expression was normalized to GAPDH and presented as
fold change vs. the control. Data expressed as mean ± SD were the results of three independent experiments from different litters of rats for each treatment, and
analyzed by One-way ANOVA. Significant difference was defined as p < 0.05, and *, vs. blank control; +, vs. exposure group; #, vs. low dose intervention group;
&, vs. middle dose intervention group.
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FIGURE 4 | Involvement of ERK in MMP-2 induction in primary cultured astrocytes exposed to 2-CE. I to VII represent the blank control, solvent control,
inhibitor control, exposure group, and low, middle and high dose of U0126 inhibition group, respectively. (A) Western blot analysis. Images were the representative
results of three separate experiments for each group. (B) Densitometric analysis of western blots. The relative intensity in arbitrary units was compared to β-actin and
presented as fold change vs. the control group. (C) Quantitation of mRNA by real-time RT-PCR. The gene expression was normalized to GAPDH and presented as
fold change vs. the control. Data expressed as mean ± SD were the results of three independent experiments from different litters of rats for each treatment, and
analyzed by One-way ANOVA. Significant difference was defined as p < 0.05, and *, vs. blank control;+, vs. exposure group; #, vs. low dose intervention group;
&, vs. middle dose intervention group.
et al., 2006). Accordingly, it is reasonable to assume that
upregulated protein levels of MMP-2 in the brain of mice treated
with 1,2-DCE might be partially resulted from direct effects of
2-CE generated from CYP2E1 mediated metabolism of 1,2-DCE
in vivo.
Increasing evidences have suggested that astrocytes are the
site of early dysfunction and damage induced by exogenous
chemicals (Hazell, 2002). Astrocyte activation is manifested
with an increase in proinflammatory cytokine production,
and the release of neurotoxic factors such as MMPs (Hong
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FIGURE 5 | Involvement of JNK in MMP-2 induction in primary cultured astrocytes exposed to 2-CE. I to VII represent the blank control, solvent control,
inhibitor control, exposure group, and low, middle and high dose of SP600125 inhibition group, respectively. (A)Western blot analysis. Images were the representative
results of three separate experiments for each group. (B) Densitometric analysis of western blots. The relative intensity in arbitrary units was compared to β-actin and
presented as fold change vs. the control group. (C) Quantitation of mRNA by real-time RT-PCR. The gene expression was normalized to GAPDH and presented as
fold change vs. the control. Data expressed as mean ± SD were the results of three independent experiments from different litters of rats for each treatment, and
analyzed by One-way ANOVA. Significant difference was defined as p < 0.05, and *, vs. blank control;+, vs. exposure group; #, vs. low dose intervention group;
&, vs. middle dose intervention group.
et al., 2005; Rosenberg, 2009; Lew et al., 2013). Although the
pathophysiological processes of brain edema are not completely
understood, many reports have indicated that activation of
astrocytes and the subsequent release of proinflammatory factors
and neurotoxic factors might contribute to breakdown in BBB
integrity (Cho et al., 2013; Malinsky et al., 2013). Therefore,
generation of 2-CE in vivo might contribute to the formation of
vasogenic cerebral edema in 1,2-DCE treated mice.
Furthermore, the molecular basis of the effects of 2-CE
on modulation of MMP-2 in rat astrocytes has been assessed
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in present study, and the results clearly demonstrated that
treatment of astrocytes with 2-CE could activate the MAPK
signal pathway by enhancing the protein phosphorylation of
p38, ERK1/2, and JNK1/2, which increased 705, 845, and
255%, respectively. By using the specific MAPK inhibitors, the
relationship between upregulation of MMP-2 expression and
activation of MAPK signal pathways was further investigated in
2-CE treated astrocytes. The protein levels of MMP-2 decreased
markedly in response to suppressed protein levels of p-p38 and
p-JNK1/2. However, the protein levels of MMP-2 in astrocytes
did not change markedly in response to suppressed protein levels
of p-ERK1/2. Thus, our results suggested that treatment of 2-CE
could upregulate the protein levels of MMP-2 through activation
of p-38 MAPK and JNK signal pathway. In another words,
activation of MAPK signal pathways could play the key roles in
upregulation of MMP-2 expression in 2-CE treated astrocytes.
The roles of MAPK signal pathways in modulation of MMP-
2 expression have been testified by previous studies. It has been
reported that the specific MAPK inhibitor effectively reduced the
MMP-2 levels in rat cortical cultures after mechanical trauma
injury (Wang et al., 2002). Additionally, study reported by Qin
et al. (2015) disclosed that treatment with LPS decreased the
mRNA and protein levels of occludin and ZO-1, and enhanced
the phosphorylation of p38 MAPK and JNK, and expression of
MMP-2 in the cerebral microvascular endothelial cells, which
were attenuated by pretreatment with SB203580 or SP600125,
which suggested that activation of p38 MAPK and JNK pathways
were involved in the LPS-induced MMP-2 overexpression, and
in turn contributed to disruption of blood brain barrier integrity.
Thus, our results were consistent with their findings.
It has been well established that p38 was the first protein
isolated from MAPK signal pathways, and plays the central roles
in inflammation (Wu et al., 2004; Borders et al., 2008; Kant et al.,
2011; Yang et al., 2014). It can be strongly activated by various
stress conditions and inflammatory cytokines, and then migrates
from the cytosol into nucleus or can transfer to the other parts
of the cell, where it activates transcription factors or downstream
kinases (Arthur and Ley, 2013). JNK has been shown to play the
crucial roles in controlling cell proliferation and apoptosis. It is
strongly activated in response to a variety of stress signals (Bas
et al., 2015). The activation of JNK pathway could also result in
gene transcription (Verma and Datta, 2012). ERKs in general,
are pivotal regulators of proliferation and differentiation. They
can be activated by many factors, and then translocate to the
nucleus, where they activate various transcription factors, and
ultimately leading to changes in gene expression (Wang et al.,
2002; Piao et al., 2003; Fujimoto et al., 2007; Wu et al., 2010;
Huang et al., 2013; Gladbach et al., 2014). Because the three kinds
of MAPK signal pathways possess many similarities, they may
undergo cross-talk at several levels. Until now, the accumulated
evidence suggested that MMP-2 expression was regulated by
the p38, ERK1/2 and JNK1/2 signal pathways in different cell
types (Lee et al., 2014; Kim et al., 2015). However, to our
knowledge this was the first report to demonstrate the molecular
mechanisms underlying MMP-2 upregulation in 2-CE treated rat
astrocytes.
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